The FDA Told Its Own Panel These Peptides Weren't Ready. The Panel Voted Yes Anyway

Every drug that reaches a pharmacy shelf in the United States is supposed to clear the same bar: real trials, real data, a paper trail proving it works and won't hurt people. On July 23, an FDA advisory panel voted to let specialty pharmacies start making four peptides that have never cleared that bar — over the written objections of the FDA's own scientists.

The vote covered BPC-157, KPV, TB-500, and MOTS-c: injectable compounds sold today mostly through gray-market websites stamped "for research use only," but used by a growing number of Americans chasing faster injury recovery, weight loss, or general anti-aging benefits. The Pharmacy Compounding Advisory Committee (PCAC) voted 8-6, with one abstention, to add BPC-157 and KPV to the FDA's list of substances compounding pharmacies can legally produce. MOTS-c and TB-500 passed by similar margins, according to NPR's coverage and KPBS's report of the same meeting. Three more peptides — Emideltide, Epitalon, and Semax — go before the same panel on a second day of voting.

The vote isn't binding. The FDA can still reject the recommendation, though NPR notes the agency has only overridden this panel once before.

What the FDA's own scientists said

Before the panel voted, FDA staff had already told them not to. According to NPR reporter Will Stone, the agency's reviewers found that most of the evidence behind BPC-157 — a peptide based on a compound found in human stomach juices — comes from animal studies, with "quite limited" human data. FDA official Russell Wesdyk went further during the meeting, arguing there's a "foundational challenge" that predates any safety question: the agency can't even pin down a consistent chemical definition of what's being sold as BPC-157, since formulations vary between suppliers. "We can't create quality standards until we actually know what it is," he said, as quoted by NPR.

That objection didn't move the panel. One member, Dr. Brian Lee of USC's Keck School of Medicine, voted no and said publicly he worried the FDA's endorsement "can be potentially harmful" given how little the public knows about the actual evidence base. Others disagreed just as openly — Dr. Kris Wusterhausen, a Texas physician who runs a peptide-therapy practice, told the panel "once you see the effects of BPC, you can't unsee it."

Where the coverage splits

Three different framings emerged from outlets covering the same eight-hour meeting, and the differences say as much about what each newsroom thinks the story is about as they do about the vote itself.

STAT News, which covers FDA policy for a biotech-industry audience, led with the political angle. Its headline called the outcome "a win for RFK Jr." — Health Secretary Robert F. Kennedy Jr. has publicly pushed to loosen peptide restrictions as part of his broader wellness agenda. STAT's reporting also dug into who is actually sitting on the panel: in a separate piece published the same day, the outlet noted the committee was recently overhauled, and several new members — including pharmacist and Tennessee state senator Bobby Harshbarger, whose mother is a sitting member of Congress who has lobbied HHS for looser peptide rules — have direct financial or family ties to the industry the vote benefits. STAT flagged this as a conflict-of-interest story first and a science story second.

CNN took the opposite approach. Its piece, "The future of peptides in the US is about to become clearer", is framed as a consumer explainer: what peptides are, why wellness influencers like them, and how a shift to compounding pharmacies might parallel the loose regulatory treatment already given to dietary supplements. There's no mention of Kennedy's advocacy or the panel's makeup — the FDA process is background, not the point.

The Washington Times split the difference, running the vote through a culture-war lens with the headline "FDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers," tying the substance to podcaster-driven demand rather than to Kennedy or the committee's composition. NBC News and Time both used a more procedural frame — a vote that went ahead "despite" agency scientists' objections — without pursuing the industry-ties angle STAT raised.

None of these framings is wrong. They're each answering a different question: is this a story about political appointees reshaping an agency, a story about a wellness trend going mainstream, or a story about a regulator overruling its own experts? The vote supports all three readings, and which one a reader encounters depends entirely on which outlet's RSS feed they happened to open.

The part most coverage skipped

Almost no outlet dwelt on Wesdyk's chemistry point, which is arguably the most consequential fact in the room: if the FDA can't define what BPC-157 is at a molecular level, "compounding pharmacy" oversight may not mean much in practice. Compounded drugs are already held to a lower evidence bar than FDA-approved ones — that's the entire premise of compounding, meant for patients with no other options. Extending that lower bar to a substance the agency admits it cannot chemically standardize is a different kind of gap than the "unapproved but promising" framing most headlines implied.

There's also a quieter number worth sitting with: the public comment period drew close to 1,860 submissions, dominated by clinicians who sell peptides and patients who already use them. That's a real gray-market user base voicing a real preference for legal, prescribed access over unregulated imports — a legitimate public-health argument. But it's also a comment record that structurally favors the people with the most to gain from a yes vote, a dynamic advisory-committee watchers flagged well before Thursday's meeting.

Why it matters beyond the injection

If the FDA follows its panel's recommendation — which, per NPR, it usually does — millions of Americans currently buying BPC-157 and similar peptides from unregulated overseas suppliers would gain a legal, prescribed pathway. That's a genuine harm-reduction case, similar to arguments made for other public-health interventions CheckDeezOut has covered, where formal channels compete with informal ones already in wide use.

But it also sets a precedent: a health agency's advisory panel, restaffed with industry-connected members, overruling that agency's own scientific staff on a product category with almost no controlled human trials. The FDA's final decision — expected sometime after Friday's second round of votes — will determine whether that precedent becomes policy or stays a single unusual afternoon in Washington.

Sources & Further Reading

• Advisers to the FDA vote to ease regulation of popular peptides — NPR
• FDA panel backs easier access to peptides — KPBS/NPR (full meeting detail and quotes)
• In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides — STAT News
• FDA staff and peptide enthusiasts set to clash at advisory panel — STAT News (panel conflict-of-interest reporting)
• The future of peptides in the US is about to become clearer. Here's what you should know — CNN
• FDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers — The Washington Times